Key Near Term Pipeline Updates:

Rett syndrome: Top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial. Company expects to announce topline results from this study in the second half of 2023.
Alzheimer’s disease: Full data ANAVEX®2-73-AD-004, including newly available preliminary results of surrogate biomarkers of pivotal Phase 2b/3 clinical trial. The Company intends to discuss these findings with regulatory authorities in the context of the ongoing clinical development of ANAVEX®2-73 in this indication, with the goal of providing a much-needed treatment to the millions of patients living with Alzheimer’s disease with a convenient once-daily oral treatment. Company expects to announce data in the second half of 2023.
Parkinson’s disease: Initiation of ANAVEX®2-73 pivotal clinical trial.
Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused clinical trial.
Fragile X: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial.
Schizophrenia: Initiation of ANAVEX®3-71 Phase 2 clinical trial.
New Rare disease: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial.
Publications: Several clinical publications involving ANAVEX®2-73, ANAVEX®3-71 and Rett syndrome Burden of Illness study.